JPRN-jRCT2031220096招募中3 期
A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, With an Additional 18-Week Blinded Extension Period
Otani Tetsuya0 个研究点目标入组 402 人开始时间: 2022年5月28日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 402
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Diagnosed with schizophrenia at least 1 year before informed consent.
- •- Experienced a persistent psychotic episode within 1 month prior to screening requiring treatment modifications as judged by the investigator or sub-investigator.
排除标准
- •- History of clinically significant medical conditions or any other reason that the investigator (or subinvestigator) determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study drug.
研究者
相似试验
进行中（未招募）
1 期
A 16-Week Study to assess effects of Neflamapimod in Subjects with Dementia with Lewy Bodies (DLB)Dementia with Lewy Bodies (DLB)MedDRA version: 20.0Level: PTClassification code 10067889Term: Dementia with Lewy bodiesSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001566-15-NLEIP Pharma Inc91
已完成
2 期
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB)Dementia with Lewy Bodies (DLB)neurodegenerative disease10012272dementiaNL-OMON49197EIP Pharma Inc.13
进行中（未招募）
不适用
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I DepressioEUCTR2008-007482-23-DESunovion Pharmaceuticals Inc.340
进行中（未招募）
1 期
uradisone for the treatment of depression disorderEUCTR2012-004132-33-GBSunovion Pharmaceuticals Inc.209
进行中（未招募）
1 期
A 6-Week Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar DepressioBipolar depressionMedDRA version: 14.1Level: LLTClassification code 10004936Term: Bipolar depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2008-007482-23-CZSunovion Pharmaceuticals, Inc.340